MetaVia Inc. Common Stock

MTVANASDAQUSD
1.71 USD
0.09 (5.00%)AT CLOSE (11:59 AM EDT)
1.82
0.11 (6.37%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
1.82
0.11 (6.37%)
🔴Market: CLOSED

MetaVia Inc. Common Stock (MTVA) trades at $1.74 per share. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest MTVA is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jul 17, 2026.

Open?$1.78
High?$1.79
Low?$1.68
Prev. Close?$1.80
Volume?116.2K
Avg. Volume?1.1M
VWAP?$1.74
Rel. Volume?0.10x
Bid / Ask
Bid?$1.41 × 100
Ask?$2.06 × 100
Spread?$0.65
Midpoint?$1.73
Valuation & Ratios
Market Cap?9.3M
Shares Out?5.2M
Float?3.4M
Float %?65.2%
P/E Ratio?N/A
P/B Ratio?1.02
EPS?-$2.54
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
Employees
8
Market Cap
9.3M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2016-08-04
Address
545 CONCORD AVENUE
CAMBRIDGE, MA 02138
Phone: (857) 702-9600
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-2/3)
Medium-Term (Wave)? Bearish(-1/3)
Short-Term (Ripple)? Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
91
Piotroski F-Score?0/9Weak
Altman Z-Score?-16.23Distress
Confidence?36%Very Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?3.68%Low
Short Interest?124.0K
Days to Cover?1.0
Free Float3.4M
Avg Daily Volume204.9K
Settlement Date2026-06-30
Financial Health
Current Ratio?2.73Strong
Quick Ratio?2.73Strong
Cash Ratio?2.64Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A
P/B?
Peers
100
S&P
97
1.02CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
Peers
100
S&P
97
0.3CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-144.7%WEAK
ROA?
S&P
3
-91.2%WEAK
Cash Flow & Enterprise
FCF?$-15146000
Enterprise Value?$-4416134
Fundamentals ratios updated end of day